Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ANIK's Cash to Debt is ranked higher than
97% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. ANIK: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ANIK' s Cash to Debt Range Over the Past 10 Years
Min: 1.7  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.91
ANIK's Equity to Asset is ranked higher than
87% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ANIK: 0.91 )
Ranked among companies with meaningful Equity to Asset only.
ANIK' s Equity to Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.80 Max: 0.92
Current: 0.91
0.51
0.92
Interest Coverage No Debt
ANIK's Interest Coverage is ranked higher than
96% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ANIK: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ANIK' s Interest Coverage Range Over the Past 10 Years
Min: 38.66  Med: 5127.88 Max: 9999.99
Current: No Debt
38.66
9999.99
F-Score: 4
Z-Score: 18.45
M-Score: -2.87
WACC vs ROIC
16.24%
47.41%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 53.46
ANIK's Operating margin (%) is ranked higher than
96% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. ANIK: 53.46 )
Ranked among companies with meaningful Operating margin (%) only.
ANIK' s Operating margin (%) Range Over the Past 10 Years
Min: 11.81  Med: 21.47 Max: 58.19
Current: 53.46
11.81
58.19
Net-margin (%) 34.22
ANIK's Net-margin (%) is ranked higher than
93% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. ANIK: 34.22 )
Ranked among companies with meaningful Net-margin (%) only.
ANIK' s Net-margin (%) Range Over the Past 10 Years
Min: 7.77  Med: 16.82 Max: 36.29
Current: 34.22
7.77
36.29
ROE (%) 17.45
ANIK's ROE (%) is ranked higher than
91% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. ANIK: 17.45 )
Ranked among companies with meaningful ROE (%) only.
ANIK' s ROE (%) Range Over the Past 10 Years
Min: 5.16  Med: 11.29 Max: 24.43
Current: 17.45
5.16
24.43
ROA (%) 15.82
ANIK's ROA (%) is ranked higher than
94% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. ANIK: 15.82 )
Ranked among companies with meaningful ROA (%) only.
ANIK' s ROA (%) Range Over the Past 10 Years
Min: 3.27  Med: 7.61 Max: 21.97
Current: 15.82
3.27
21.97
ROC (Joel Greenblatt) (%) 88.10
ANIK's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. ANIK: 88.10 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ANIK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 13.35  Med: 40.48 Max: 110.18
Current: 88.1
13.35
110.18
Revenue Growth (3Y)(%) 6.90
ANIK's Revenue Growth (3Y)(%) is ranked higher than
54% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ANIK: 6.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ANIK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -4.4  Med: 7.50 Max: 26.9
Current: 6.9
-4.4
26.9
EBITDA Growth (3Y)(%) 23.00
ANIK's EBITDA Growth (3Y)(%) is ranked higher than
78% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. ANIK: 23.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ANIK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -64.4  Med: 30.65 Max: 91.7
Current: 23
-64.4
91.7
EPS Growth (3Y)(%) 34.80
ANIK's EPS Growth (3Y)(%) is ranked higher than
86% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. ANIK: 34.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ANIK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.2  Med: 29.80 Max: 75.8
Current: 34.8
-66.2
75.8
» ANIK's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-29)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

ANIK Guru Trades in Q2 2015

Jim Simons 117,200 sh (+4.18%)
John Burbank Sold Out
Joel Greenblatt 258,483 sh (-7.21%)
» More
Q3 2015

ANIK Guru Trades in Q3 2015

Jim Simons 53,600 sh (-54.27%)
Joel Greenblatt 89,187 sh (-65.50%)
» More
Q4 2015

ANIK Guru Trades in Q4 2015

Chuck Royce 59,265 sh (New)
Ken Fisher 14,124 sh (New)
Jim Simons 113,000 sh (+110.82%)
Joel Greenblatt 104,446 sh (+17.11%)
» More
Q1 2016

ANIK Guru Trades in Q1 2016

Ken Fisher 57,719 sh (+308.66%)
» More
» Details

Insider Trades

Latest Guru Trades with ANIK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 19.74
ANIK's P/E(ttm) is ranked higher than
65% of the 239 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. ANIK: 19.74 )
Ranked among companies with meaningful P/E(ttm) only.
ANIK' s P/E(ttm) Range Over the Past 10 Years
Min: 8.66  Med: 20.24 Max: 46.11
Current: 19.74
8.66
46.11
Forward P/E 23.26
ANIK's Forward P/E is ranked lower than
69% of the 85 Companies
in the Global Biotechnology industry.

( Industry Median: 17.79 vs. ANIK: 23.26 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 19.74
ANIK's PE(NRI) is ranked higher than
66% of the 242 Companies
in the Global Biotechnology industry.

( Industry Median: 30.06 vs. ANIK: 19.74 )
Ranked among companies with meaningful PE(NRI) only.
ANIK' s PE(NRI) Range Over the Past 10 Years
Min: 8.57  Med: 20.19 Max: 46.32
Current: 19.74
8.57
46.32
Price/Owner Earnings (ttm) 18.25
ANIK's Price/Owner Earnings (ttm) is ranked higher than
71% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 36.86 vs. ANIK: 18.25 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ANIK' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 12.25  Med: 27.74 Max: 294.58
Current: 18.25
12.25
294.58
P/B 3.21
ANIK's P/B is ranked higher than
50% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. ANIK: 3.21 )
Ranked among companies with meaningful P/B only.
ANIK' s P/B Range Over the Past 10 Years
Min: 0.58  Med: 2.36 Max: 4.63
Current: 3.21
0.58
4.63
P/S 7.28
ANIK's P/S is ranked higher than
60% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. ANIK: 7.28 )
Ranked among companies with meaningful P/S only.
ANIK' s P/S Range Over the Past 10 Years
Min: 1  Med: 3.81 Max: 9.14
Current: 7.28
1
9.14
PFCF 22.61
ANIK's PFCF is ranked higher than
59% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 30.80 vs. ANIK: 22.61 )
Ranked among companies with meaningful PFCF only.
ANIK' s PFCF Range Over the Past 10 Years
Min: 10.44  Med: 19.58 Max: 1111.54
Current: 22.61
10.44
1111.54
POCF 17.25
ANIK's POCF is ranked higher than
62% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. ANIK: 17.25 )
Ranked among companies with meaningful POCF only.
ANIK' s POCF Range Over the Past 10 Years
Min: 8.89  Med: 18.29 Max: 1073.75
Current: 17.25
8.89
1073.75
EV-to-EBIT 10.16
ANIK's EV-to-EBIT is ranked higher than
71% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.28 vs. ANIK: 10.16 )
Ranked among companies with meaningful EV-to-EBIT only.
ANIK' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.8  Med: 10.50 Max: 37.9
Current: 10.16
1.8
37.9
EV-to-EBITDA 9.62
ANIK's EV-to-EBITDA is ranked higher than
71% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 20.97 vs. ANIK: 9.62 )
Ranked among companies with meaningful EV-to-EBITDA only.
ANIK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.4  Med: 9.00 Max: 34
Current: 9.62
1.4
34
PEG 0.62
ANIK's PEG is ranked higher than
87% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 2.25 vs. ANIK: 0.62 )
Ranked among companies with meaningful PEG only.
ANIK' s PEG Range Over the Past 10 Years
Min: 0.29  Med: 0.58 Max: 30.56
Current: 0.62
0.29
30.56
Shiller P/E 46.15
ANIK's Shiller P/E is ranked higher than
59% of the 51 Companies
in the Global Biotechnology industry.

( Industry Median: 54.60 vs. ANIK: 46.15 )
Ranked among companies with meaningful Shiller P/E only.
ANIK' s Shiller P/E Range Over the Past 10 Years
Min: 14.29  Med: 39.50 Max: 113.22
Current: 46.15
14.29
113.22
Current Ratio 10.21
ANIK's Current Ratio is ranked higher than
76% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. ANIK: 10.21 )
Ranked among companies with meaningful Current Ratio only.
ANIK' s Current Ratio Range Over the Past 10 Years
Min: 2.91  Med: 7.01 Max: 23.08
Current: 10.21
2.91
23.08
Quick Ratio 9.35
ANIK's Quick Ratio is ranked higher than
75% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. ANIK: 9.35 )
Ranked among companies with meaningful Quick Ratio only.
ANIK' s Quick Ratio Range Over the Past 10 Years
Min: 2.45  Med: 6.05 Max: 21
Current: 9.35
2.45
21
Days Inventory 220.70
ANIK's Days Inventory is ranked lower than
76% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. ANIK: 220.70 )
Ranked among companies with meaningful Days Inventory only.
ANIK' s Days Inventory Range Over the Past 10 Years
Min: 98.12  Med: 146.30 Max: 237.04
Current: 220.7
98.12
237.04
Days Sales Outstanding 54.14
ANIK's Days Sales Outstanding is ranked higher than
59% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. ANIK: 54.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
ANIK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.73  Med: 88.04 Max: 109.78
Current: 54.14
47.73
109.78
Days Payable 53.73
ANIK's Days Payable is ranked lower than
56% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. ANIK: 53.73 )
Ranked among companies with meaningful Days Payable only.
ANIK' s Days Payable Range Over the Past 10 Years
Min: 20.94  Med: 62.17 Max: 169.68
Current: 53.73
20.94
169.68

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.44
ANIK's Price/Net Cash is ranked lower than
53% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: 5.42 vs. ANIK: 6.44 )
Ranked among companies with meaningful Price/Net Cash only.
ANIK' s Price/Net Cash Range Over the Past 10 Years
Min: 0.48  Med: 6.33 Max: 12.72
Current: 6.44
0.48
12.72
Price/Net Current Asset Value 4.84
ANIK's Price/Net Current Asset Value is ranked higher than
56% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. ANIK: 4.84 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ANIK' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.34  Med: 4.37 Max: 40.16
Current: 4.84
0.34
40.16
Price/Tangible Book 3.55
ANIK's Price/Tangible Book is ranked higher than
55% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. ANIK: 3.55 )
Ranked among companies with meaningful Price/Tangible Book only.
ANIK' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.29  Med: 2.84 Max: 5.43
Current: 3.55
0.29
5.43
Price/Projected FCF 1.46
ANIK's Price/Projected FCF is ranked higher than
79% of the 176 Companies
in the Global Biotechnology industry.

( Industry Median: 3.66 vs. ANIK: 1.46 )
Ranked among companies with meaningful Price/Projected FCF only.
ANIK' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.48  Med: 1.81 Max: 17.71
Current: 1.46
0.48
17.71
Price/DCF (Earnings Based) 0.71
ANIK's Price/DCF (Earnings Based) is ranked higher than
89% of the 18 Companies
in the Global Biotechnology industry.

( Industry Median: 1.15 vs. ANIK: 0.71 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.88
ANIK's Price/Median PS Value is ranked lower than
80% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. ANIK: 1.88 )
Ranked among companies with meaningful Price/Median PS Value only.
ANIK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.12  Med: 1.13 Max: 1.96
Current: 1.88
0.12
1.96
Price/Peter Lynch Fair Value 0.87
ANIK's Price/Peter Lynch Fair Value is ranked higher than
84% of the 57 Companies
in the Global Biotechnology industry.

( Industry Median: 1.86 vs. ANIK: 0.87 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ANIK' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.37  Med: 0.90 Max: 1.67
Current: 0.87
0.37
1.67
Price/Graham Number 1.75
ANIK's Price/Graham Number is ranked higher than
57% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. ANIK: 1.75 )
Ranked among companies with meaningful Price/Graham Number only.
ANIK' s Price/Graham Number Range Over the Past 10 Years
Min: 0.5  Med: 1.61 Max: 5.57
Current: 1.75
0.5
5.57
Earnings Yield (Greenblatt) (%) 9.81
ANIK's Earnings Yield (Greenblatt) (%) is ranked higher than
92% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. ANIK: 9.81 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ANIK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.6  Med: 9.50 Max: 56.4
Current: 9.81
2.6
56.4
Forward Rate of Return (Yacktman) (%) 41.95
ANIK's Forward Rate of Return (Yacktman) (%) is ranked higher than
91% of the 108 Companies
in the Global Biotechnology industry.

( Industry Median: 13.93 vs. ANIK: 41.95 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ANIK' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -11.2  Med: 7.65 Max: 54.6
Current: 41.95
-11.2
54.6

More Statistics

Revenue(Mil) $100
EPS $ 2.23
Beta1.92
Short Percentage of Float14.22%
52-Week Range $30.93 - 49.25
Shares Outstanding(Mil)14.33

Analyst Estimate

Dec16 Dec17
Revenue(Mil) 98 111
EPS($) 1.62 1.87
EPS without NRI($) 1.62 1.87

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:MACK, SZSE:002604, XMCE:ROVI, NAS:CEMP, XBRU:ABLX, ROCO:4105 » details
Traded in other countries:AKP.Germany,
Anika Therapeutics Inc was incorporated in 1992 as a Massachusetts company. The Company develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid, or HA, a naturally occurring, biocompatible polymer found throughout the body. Due to its biophysical and biochemical properties, HA performs physiological functions such as the protection and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues, and the transport of molecules to and within cells. The Company through its subsidiary has over 20 products currently commercialized, mainly in Europe. These products are made from hyaluronic acid, based on two technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA. Both technologies are protected by a portfolio of owned and licensed patents. The Company offers therapeutic products in various areas which include: Orthobiologics, Dermal, Surgical, Ophthalmic and Veterinary. Its Orthobiologics products consist of joint health and orthopedic products. These products are used in a range of treatments from providing relief from the pain of osteoarthritis, to regenerating damaged tissue such as cartilage defects. Its joint health products include ORTHOVISC, ORTHOVISC mini, and MONOVISC. ORTHOVISC is available in the U.S., Canada, Turkey and other international markets for the treatment of osteoarthritis of the knee, and in Europe for the treatment of osteoarthritis in all joints. Its Dermal products consist of wound care products, based on the HYAFF technology, and aesthetic dermal fillers. The HYAFF technology offers products for the treatment of skin wounds, ranging from burns to diabetic ulcers. The products cover a variety of wound treatment solutions including debridement agents,therapies to aid healing and skin substitutes. Its ophthalmic business includes HA viscoelastic products used in ophthalmic surgery. These products include AMVISC and AMVISC Plus product line, STAARVISC-IITM, Optivisc, AnikaVisc and AnikaVisc Plus which are injectable, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures such as cataract extraction and intraocular lens implantation. Its surgical business consists of products used to prevent surgical adhesions, and to treat ENT disorders. Hyalobarrier is a clinically post-operative adhesion barrier for use in the abdomino-pelvic area. The product is currently commercialized in Europe, the Middle East and certain Asian countries through a distribution network, but is not approved in the U.S. INCERT, approved for sale in Europe, Turkey, and Malaysia. It is chemically modified, cross-linked HA product for the prevention of spinal post-surgical adhesions. The Company along with its subsidiary offers products used in connection with the treatment of ENT disorders. The products are Merogel, a woven fleece nasal
» More Articles for ANIK

Headlines

Articles On GuruFocus.com
Four Stocks With Growing EPS Near Their 52-Week Lows - Part II Jul 02 2015 
WEEKLY CFO SELLS HIGHLIGHT: ANIK, GILD, PETM, NKE, ADBE Mar 31 2013 
Anika Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Anika Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Anika Therapeutics Inc. Reports Operating Results (10-Q) Nov 03 2009 
Anika Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2009 
Anika Therapeutics Inc. Reports Operating Results (10-Q) May 05 2009 

More From Other Websites
ANIKA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report May 03 2016
ETF’s with exposure to Anika Therapeutics, Inc. : May 2, 2016 May 02 2016
Anika Therapeutics, Inc. :ANIK-US: Earnings Analysis: Q1, 2016 By the Numbers Apr 29 2016
Anika Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ANIK-US : April... Apr 29 2016
Anika’s Arthritis Treatment Gains Acceptance Among MDs, And Traders Apr 28 2016
Edited Transcript of ANIK earnings conference call or presentation 28-Apr-16 1:00pm GMT Apr 28 2016
Anika Therapeutics Inc Earnings Call scheduled for 9:00 am ET today Apr 28 2016
Immunomedics (IMMU) Catches Eye: Stock Moves 10.8% Higher Apr 28 2016
Anika beats 1Q profit forecasts Apr 27 2016
Anika beats 1Q profit forecasts Apr 27 2016
Anika Reports First Quarter 2016 Financial Results Apr 27 2016
ANIKA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Apr 27 2016
Anika Reports First Quarter 2016 Financial Results Apr 27 2016
New Strong Buy Stocks for April 27th Apr 27 2016
Anika Therapeutics downgraded by Northland Capital Apr 27 2016
Q1 2016 Anika Therapeutics Inc Earnings Release - After Market Close Apr 27 2016
Oncothyreon (ONTY) Catches Eye: Stock Moves 11.6% Higher Apr 26 2016
Cytori Therapeutics (CYTX) Shows Strength: Stock Up 13.2% Apr 19 2016
Edge Therapeutics (EDGE) in Focus: Stock Rises 6.7% Apr 14 2016
Anika Therapeutics to Issue First-Quarter 2016 Financial Results and Business Highlights on... Apr 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK